The dose–response effect of insulin sensitivity on albuminuria in children according to diabetes type by Mottl, Amy K. et al.
The dose response effect of insulin sensitivity on albuminuria in 
children according to diabetes type
Amy K Mottl1, Jasmin Divers2, Dana Dabelea3, David M Maahs4, Lawrence Dolan5, David 
Pettitt6, Santica Marcovina7, Giuseppina Imperatore8, Catherine Pihoker9, Michael Mauer10, 
and Elizabeth J Mayer-Davis11 for the SEARCH for Diabetes in Youth Study
1UNC Division of Nephrology and Hypertension, University of North Carolina School of Medicine, 
Chapel Hill, NC
2Dept of Biostatistical Sciences, Wake Forest School of Medicine, Winston Salem, NC
3Dept of Epidemiology, School of Public Health, University of Colorado Denver, Aurora CO
4Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora CO
5Division of Endocrinology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
6Santa Barbara CA
7Northwest Lipid Metabolism and Diabetes Research Laboratories, Dept. of Medicine, University 
of Washington, Seattle, WA
8Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health 
Promotion, Centers for Disease Control and Prevention, Atlanta, GA
9Dept of Pediatrics, University of Washington, Seattle, WA
10Depts of Pediatrics and Medicine, University of Minnesota Medical School, Minneapolis, MN
11Depts of Nutrition and Medicine, University of North Carolina Schools of Public Health and 
Medicine, Chapel Hill NC
Abstract
Background—Insulin resistance is associated with microalbuminuria among youth with diabetes 
mellitus. We sought to determine the dose-response effect of insulin sensitivity (IS) on the 
magnitude of albuminuria and whether there is a threshold below which urine albumin excretion 
increases.
Methods—These analyses included participants from the SEARCH for Diabetes in Youth Study 
with incident diabetes who completed a baseline study visit (N = 2988). We estimated IS using a 
validated equation incorporating waist circumference, HbA1C and fasting serum triglycerides. 
Ethics statement
The study protocol was reviewed and approved by local institutional review boards (IRB) that had jurisdiction over the local study 
populations. Consent was obtained from parents of all participants under age 18 years and assent from participants according to the 
specific age requirement deemed by the local IRB.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention and the National Institute of Diabetes and Digestive and Kidney Disease
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Multivariate regression analyses were performed to assess the effect of IS on urine albumin 
creatinine ratio (UACR), stratified by diabetes type. The IS threshold was then determined using 
segmented regressions within each diabetes type and incorporated into the multivariate model.
Results—There was an association between IS and UACR in type 2 diabetes only (beta = −0.39; 
p <0.001). There was strong statistical evidence for a threshold effect of IS score on UACR in the 
group of youth with type 2 (beta = 0.40; p <0.001) but not type 1 diabetes (p = 0.3).
Conclusions—In cross-sectional analyses, there is a negative association between IS and UACR 
in youth with type 2 but not type 1 diabetes, and this association likely includes a threshold effect 
of IS on UACR.
Keywords
microalbuminuria; urine:albumin creatinine ratio; insulin resistance; nephropathy; metabolic 
syndrome
INTRODUCTION
The rising prevalence of diabetes in adolescents and young adults poses a major public 
health problem, as a greater lifetime diabetes exposure in this group will translate into a 
greater future burden of microvascular complications [1]. Diabetic kidney disease (DKD) 
accounts for nearly half of end-stage kidney disease in the USA, and is a major risk factor 
for cardiovascular events and death [2–4]. Although the precision of microalbuminuria as a 
predictor for increased risk is less than initially thought, the degree of albuminuria after long 
diabetes duration is still the strongest available biomarker for the risk of progressive DKD 
[5]. Albuminuria has also been noted to occur in the presence of obesity, even in the absence 
of diabetes [6, 7]. Moreover, albuminuria is more prevalent in early type 2 than type 1 
diabetes; and differences in body mass index (BMI) and hypertension do not completely 
explain this difference [8]. It is possible that insulin resistance could explain the higher 
levels of urinary albumin associated with obesity and type 2 diabetes.
In a previous study from SEARCH, we analyzed the urine albumin:creatinine ratio (UACR) 
across four etiologic diabetes sub-groups categorized according to diabetes autoantibody 
(DAA) status (DAA + versus -) and insulin sensitivity (IS) status. We found that the UACR 
levels among participants in the DAA-/insulin resistant group were significantly higher than 
those observed in all other groups, even after multivariable adjustment. To explore the 
underlying factors that accounted for the difference in UACR between the two insulin 
resistance groups, we performed multivariable regression analyses restricted to these two 
groups. Only the degree of IS was significantly associated with UACR (β = −0.54; p 
<0.0001), suggesting that the difference between the insulin resistant DAA+ versus DAA-
groups was due to a greater degree of insulin resistance in the DAA-group. Herein, we 
propose to extend these analyses to determine: 1) whether the association between IS and 
UACR differs by diabetes type (defined by provider diagnosis), sex or race/ethnicity, and 2) 
whether there is a threshold of IS below which urine albumin excretion increases.
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METHODS
Population
The SEARCH for Diabetes in Youth Study is a multicenter, observational, population-based 
study of youth with diabetes. A detailed description of study methods has been published 
previously [9]. SEARCH investigators have conducted population-based ascertainment of 
incident cases of diabetes in youth aged less than 20 years old from 2002 onwards. Cases 
were ascertained from geographically defined populations in Ohio, Colorado, South 
Carolina and Washington, among enrollees in one health plan in California, and Indian 
Health Service participants from four American Indian populations. Youth identified with 
incident, non-secondary diabetes were invited for a baseline study visit. Self-reported race 
and ethnicity were collected using the 2000 U.S. Census questions [10].
Sample selection, design and measurements
This cross-sectional analysis explored the association between diabetes type and the 
magnitude of albuminuria. Inclusion criteria consisted of having an in-person visit, on 
average 10 months after the diagnosis of diabetes, where fasting blood was drawn, urine was 
collected and anthropometric measurements taken (n = 2988). Individuals taking angiotensin 
converting enzyme inhibitors or angiotensin receptor blockers were excluded from these 
analyses (n = 38). Diabetes type was defined by the health care provider diagnosis. The 
study visit included measurement of waist circumference using the National Health and 
Nutrition Examination Survey protocol [11], systolic and diastolic blood pressures (SBP; 
DBP), height and weight, as previously described [12]. BMI (kg/m2) was converted to z-
scores using the standard Centers for Disease Control and Prevention approach [13].
Blood and single, random urine samples were obtained under conditions of metabolic 
stability, defined as no episodes of diabetic ketoacidosis in the preceding month and the 
absence of fever and acute infections. Urine was not collected from girls who were 
menstruating. Specimens were processed locally and shipped within 24 hours to the central 
laboratory (Northwest Lipid Metabolism and Diabetes Research Laboratories, Seattle, WA). 
Measurements of serum cholesterol, triglycerides (TG) and high density lipoprotein (HDL) 
cholesterol were performed using Roche reagent on a Roche Module P autoanalyzer (Roche 
Diagnostics, Indianapolis, IN). HbA1c was measured by a dedicated ion exchange high–
performance liquid chromatography instrument (TOSOH Bioscience).
A random urine specimen was used for calculation of UACR. Urinary creatinine was 
measured on the Roche Modular P autoanalyzer by the Roche enzymatic method with 
calibrator values traceable to the isotope dilution mass spectroscopy reference procedure. 
Two quality-control samples were analyzed in each run, and the inter-assay coefficient of 
variation was consistently <2 %. Urine albumin was measured immunochemically using 
Siemens reagent on a Siemens BNII nephelometer. The inter-assay coefficient of variation 
was <5 % for the high and <6.5 % for the low-level quality-control sample. We defined 
albuminuria as a UACR 30 μg/mg as recommended by the American Diabetes Association 
guidelines [14] and the National Kidney Disease Outcomes Quality Initiative [15].
Mottl et al. Page 3
Pediatr Nephrol. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
We estimated IS using a validated equation based on euglycemic hyperinsulinemic clamp 
data as follows:
This equation was developed and validated using direct measurements of glucose disposal 
rate (GDR) from euglycemic-hyperinsulinemic clamps conducted among 85 SEARCH 
participants, and 22 matched non-diabetic control subjects [16]. As previously reported, we 
defined insulin resistance among SEARCH participants in this study as IS below the 25th 
percentile for the U.S. general youth population (IS < 8.15) [17].
Blood samples taken at the baseline visit were analyzed for the 65-kD isoform of glutamate 
decarboxylase and insulinoma-associated-2 antibodies using the NIDDK standardized 
method [18]. The cutoff values for positivity were 33 DK units/mL for GADA and 5 DK 
units/mL for IA-2A. The specificity and sensitivity were 97 and 76 %, respectively for 
GADA, and 99 and 64 %, respectively for IA-2A [18]. Positive titers for either GADA or 
IA-2A were used to define DAA positivity. Because many participants were treated with 
insulin, analysis of insulin autoantibodies was not performed.
Statistical analysis
We performed statistical analyses using SAS software, version 9.3 (SAS Institute, Cary, NC) 
and R (R Core Team, 2015) [19]. The sample sizes for youth from race/ethnic groups other 
than non-Hispanic white were small. Hence, all racial/ethnic groups other than non-Hispanic 
white were combined into a single ‘minority’ category. The means and percentages of the 
demographic and clinical characteristics were compared between diabetes types, based on 
their health care provider’s diagnosis, using chi square and Wilcoxon two-sample test, which 
is more robust to deviations from the assumption of normality.
Multivariate regression analyses were performed to assess the relationship between IS and 
UACR. The logarithm of UACR was used as the outcome. Covariates included age, sex, 
race/ethnicity, DAA positivity, diabetes duration and SBP z-score. A-priori, the decision was 
made to leave HbA1c out of the model due to the fact that HbA1c is incorporated into the 
calculation of IS. Measurements of body size were also left out of the model because waist 
circumference was also incorporated into the IS calculation, and this measure is collinear 
with other parameters reflecting BMI.
Interaction analyses—We tested interaction between diabetes type and IS within the 
combined cohort first, and if the interaction term was significant to p <0.05 all subsequent 
analyses were stratified by diabetes type. Additional IS*sex and IS*ethnicity interactions 
were also explored within each diabetes type.
Threshold analyses—We performed threshold estimation using a segmented regression 
approach. Segmented regressions were fitted using the ‘segmented’ package in R [20]. This 
package implements an iterative procedure that starts with an initial threshold value, which 
is repeatedly updated until convergence is reached.
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RESULTS
The final sample for these analyses included 2,950 participants. Participants excluded from 
analysis due to missing urine sample (N = 527 type 1; N = 85 type 2 participants) had a few 
dissimilarities to those included in the analysis (Supplemental Table 1). The most significant 
differences were among the participants with type 1 diabetes. Those with a urine sample had 
lower fasting glucose (165 versus 187 mg/dl, <0.001) and shorter diabetes duration (9.3 
versus 10.3 months, p <0.001), than those without a urine sample.
Socio-demographic and clinical characteristics were significantly different between type 1 
and type 2 participants (Table 1). Participants with type 2 diabetes were older, 
predominantly female and from racial/ethnic minority groups. They had a lower IS score and 
HbA1c, but higher BMI, BP and lipid levels. Although microalbuminuria was more common 
in the type 2 participants, there was no statistically significant difference in the distribution 
of UACR by diabetes type, despite a numeric trend toward more elevated levels in type 2.
The interaction between IS and diabetes type was statistically significant (p <0.001) and 
therefore, all other analyses were stratified. IS was significantly associated with UACR in 
participants with type 2 diabetes (p <0.001), but not type 1 diabetes (p = 0.25). Interactions 
between IS and sex and IS and ethnicity on UACR were not statistically significant within 
either diabetes type.
Using a segmented regression approach, a threshold for the relationship between IS and 
UACR was detected at IS = 6.7 and IS = 4.7 for participants with type 1 and type 2 diabetes, 
respectively (Figure 1). There was clear statistical evidence for a threshold effect of IS on 
UACR in participants with type 2 (p <0.001), but not type 1 diabetes (p = 0.09). Output from 
these multivariate regression analyses are displayed in Table 2. These data indicate that in 
participants with type 2 diabetes there is an inverse relationship between IS and UACR, and 
below the IS threshold of 4.7 the relationship becomes even stronger. The performance of 
the models including versus omitting the threshold value are available in Supplemental Table 
2.
DISCUSSION
Type 2 diabetes in adolescents and young adults is a growing pandemic, making it 
imperative to better understand the potential causative factors for DKD in this inadequately 
studied population. Our findings provide novel evidence that early in the course of type 2 
diabetes in youth, the degree of albuminuria is strongly and inversely associated with the IS 
score, a validated estimate of insulin sensitivity. Moreover, the nature of this relationship in 
type 2 diabetes likely includes a threshold effect, below which the association becomes even 
stronger. In youth with type 1 diabetes, the UACR was not significantly associated with the 
IS score.
The association of IS and albuminuria in diabetes has been noted previously [21–27], 
however several aspects of our study are novel. This is the first time the association between 
IS and albuminuria has been directly compared across diabetes types. Moreover, this is the 
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only investigation of IS and albuminuria in an inception cohort of diabetes, giving insight 
into IS as a potential pathogenic factor early in the natural history of albuminuria.
The association of albuminuria and low IS, or a surrogate abdominal adiposity, has been 
recognized in type 2 diabetes [24–30], in type 1 diabetes [21, 23, 31–35] and in populations 
without diabetes [7, 36, 37]. The few negative studies have been from populations with 
distinct characteristics such as hypertensive individuals or those without significant 
representation of overweight [25, 29]. The basis for a lack of association between 
albuminuria and IS in our youth with type 1 diabetes can only be speculated about, but it 
may be due, in part, to a relative lower prevalence of obesity, insulin resistance and 
albuminuria at this early stage of type 1 diabetes (Table 1). As shown in Figure 1, the 
association of IS and albuminuria in type 2 diabetes is most significant in the lowest portion 
of IS, and very few participants with type 1 diabetes were within this range. Previous 
SEARCH data have indicated that, although the prevalence of overweight is higher in youth 
with type 1 diabetes than in non-diabetic youth, the prevalence of obesity is actually 
somewhat lower [38]. The Epidemiology of Diabetes Interventions and Complications Study 
documented weight gain and increased abdominal adiposity in type 1 patients over time, as 
well as its association with increased vascular disease [39]. Studies of adult type 1 diabetic 
populations have clearly shown low IS to be predictive of subsequent micro- and 
macroalbuminuria [21, 23, 31–35]. Similarly, higher levels of IS in older type 1 diabetic 
populations predicted regression of microalbuminuria [40]. These studies were conducted in 
populations with type 1 diabetes with a duration of 10 – 20 years, mean BMI of 25 – 30 and 
a prevalence of microalbuminuria of 18 – 44 %; all characteristics very distinct from our 
population [23, 31, 32].
Another potential explanation for our findings is the difference in age of onset and 
consequent pubertal diabetes duration. The vast majority of SEARCH participants with type 
2 diabetes were in the peri- or post-pubertal phase at examination (age >12 years), whereas 
the minority of participants with type 1 diabetes had reached puberty. Data regarding the 
effect of puberty on diabetic complications has mostly emanated from studies of type 1 
diabetes [41]. Several older studies suggested that pre-pubertal diabetes conferred protection 
against diabetic complications. Moreover, the pubertal phase may exacerbate complications 
due to changes in the hormonal balance and increasing adiposity and insulin resistance seen 
in puberty. While we did adjust our analyses for age and diabetes duration, we did not 
specifically address pubertal phase. We intend to explore this issue further with subsequent 
longitudinal data, when more participants have passed the pubertal phase.
The association between IS and albuminuria is likely multifactorial. Hypotheses include 
increased inflammatory mediators produced in visceral adipocytes, increased circulating 
levels of insulin and impaired insulin signaling within the podocyte [42–45]. Decreasing IS 
results in aberrations in adipocytokines, including decreased adiponectin and increased 
leptin and resistin concentrations [42]. Low levels of adiponectin found in obese states have 
been linked to increased reactive oxygen species, podocyte foot process effacement, 
endothelial cell dysfunction and albuminuria [43]. Leptin levels rise with insulin resistance, 
even independent of BMI, and have been found to result in increased TGF-β and collagen 
deposition [42, 44].
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Insulin infusion has been cited to induce transient albuminuria, and its overproduction has 
been hypothesized as a mechanism by which albuminuria occurs in the insulin resistant 
state. Insulin stimulates the renin-angiotensin system, growth factors and reactive oxygen 
species [46]. Alternatively, aberrant insulin signaling has direct implications on the function 
of the podocyte which, in its normal state, is an insulin responsive cell type [45]. Supportive 
of this notion that aberrant insulin signaling in the kidney may mediate the association 
between IS and albuminuria, are numerous small studies in animals and humans showing 
insulin sensitizers to reduce urinary albumin excretion [47].
Our study has several limitations. Most importantly, only a single, random UACR was 
available for analysis. Random urine samples carry a higher inter-individual variability than 
first morning samples, and multiple urine samples are required to maximize precision in 
quantifying albuminuria [48, 49]. This is not likely to have affected our conclusions, as the 
variability in UACR is not dependent upon diabetes type or insulin sensitivity. This was also 
a cross-sectional study design and hence only associations, rather than causality, can be 
inferred from the results.
Strengths of our study include the large sample size and the ethnic and geographic diversity 
of the SEARCH study. SEARCH participants were enrolled soon after diagnosis of diabetes, 
allowing insight into the early natural history of both IS and albuminuria. Moreover, to our 
knowledge, this is the only study to examine and compare the relationships between IS and 
albuminuria in type 1 and type 2 diabetes. Our equation estimating IS was developed and 
validated in a subset of 85 SEARCH participants and 22 nondiabetic controls undergoing 
euglycemic clamps, and explained 74 % of variance of the glucose disposal rate [16]. This is 
superior to other currently available glucose disposal rate estimating equations [21, 23]. 
Although the euglycemic-hyperinsulinemic clamp study is the gold standard for 
measurement of IS, such an invasive, costly and time-consuming method is impractical for 
use in large, epidemiologic studies such as the full SEARCH study.
In conclusion, we report that in cross-sectional analyses, insulin sensitivity is significantly 
associated with albuminuria in children and adolescents with type 2 but not type 1 diabetes 
of short duration. There is likely a threshold effect of IS on UACR in type 2 diabetic 
adolescents and young adults, below which the association between IS and urine albumin 
excretion is stronger. Whether this threshold also portends an increased risk for subsequent 
micro- and macrovascular complications longitudinally, is a direction for future study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
The relationship between urine albumin:creatinine ratio and insulin sensitivity (IS) in type 1 
versus type 2 diabetic participants in the SEARCH cohort. The threshold detected in the type 
2 participants is noted by the arrow, and represents the point at which further decreases in 
insulin sensitivity are associated with even greater degrees of albuminuria.
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Table 1
Baseline characteristics of 2,950 participants in the SEARCH for Diabetes in Youth cohort, stratified by 
diabetes type.
Baseline characteristics
Type 1
mean (SD)
n=2551
Type 2
mean (SD)
n=399
p-value
Age at exam, years 11 (4) 15 (3) <0.001
Male, n (%) 1352 (53) 160 (40) <0.001
Non-Hispanic White, n (%) 1938 (76) 96 (24) <0.001
Time from diabetes diagnosis, months 10 (6) 11 (7) 0.001
Insulin sensitivity score 10.5 (3.3) 4.4 (2.2) <0.001
UACR, μg/mg (median, IQR) 7.0 (7.9) 7.4 (14.1) 0.6
Albuminuria, n (%) 202 (10) 53 (17) <0.001
HbA1c, % 7.7 (1.6) 7.2 (2.1) <0.001
Body mass index z-score 0.53 (1.02) 2.13 (0.69) <0.001
Overweight, n (%) 816 (32) 371 (93) <0.0001
SBP z-score, mmHg −0.5 (0.9) 0.39 (1.09) <0.001
DBP z-score, mmHg 0.12 (0.81) 0.52 (0.48) <0.001
Total cholesterol, mg/dl 160 (30) 171 (30) <0.001
Triglycerides, mg/dl 67 (55) 161 (182) <0.001
HDL, mg/dl 55 (13) 41 (10) <0.001
LDL, mg/dl 92 (24) 102 (30) <0.001
UACR = urine albumin:creatinine ratio; Albuminuria = UACR ≥ 30 μg/mg; SBP = systolic blood pressure; DBP = diastolic blood pressure; HDL = 
high density lipoprotein; LDL = low density lipoprotein
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Table 2
Output from multivariate linear regression ‘segmented regression threshold model’ analysis of type 2 diabetic 
participants.
Covariate
Type 1 Diabetes Type 2 Diabetes
Beta Coefficient p-value Beta Coefficient p-value
Intercept 2.366 <0.001 4.051 <0.001
Threshold 0.063 0.09 0.397 <0.001
Insulin sensitivity score −0.038 0.25 −0.385 <0.001
Age at diagnosis 0.012 0.1 −0.023 0.5
Male gender −0.341 <0.001 0.010 0.9
NonHispanic White Ethnicity −0.020 0.7 −0.1545 0.3
Diabetes autoantibodies 0.007 0.9 0.194 0.4
Systolic blood pressure Z-score −0.002 0.9 0.009 0.9
Diabetes Duration 0.004 0.9 0.007 0.5
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